Two-Year Follow-up Study of Mycobacterium tuberculosis Antigen-Driven IFN-γ Responses and Macrophage sCD14 Levels After Tuberculosis Contact

Druszczyńska, Magdalena; Włodarczyk, Marcin; Kielnierowski, Grzegorz; Kawka, Malwina; Rudnicka, Wiesława

doi:10.1007/s12088-016-0571-y

Cited by 4 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the collection of blood for DNA extraction and IGRA testing, all individuals were screened with 2 tuberculin units (TU) of M . tb PPD RT-23 (Statens Serum Institute, Copenhagen, Denmark), injected intradermally in the forearms by trained medical staff as described previously [ 7 , 8 ]. The reaction was considered positive if the diameter of skin induration measured 72 hours after PPD administration was equal or greater than 10 mm.…”

Section: Methodsmentioning

confidence: 99%

“…Just before the screening with tuberculin, the interferon-gamma release assay (IGRA) was performed in all individuals. The QuantiFERON®-TB Gold In Tube (Cellestis Limited, Carnegie, Australia) was conducted according to manufacturer’s instructions as described in detail previously [ 7 , 8 ]. The result was considered positive if the difference between IFN-γ level in plasma incubated with TB antigen and Nil control was both ≥ 0.35 IU/ml and ≥25% of Nil control value.…”

Section: Methodsmentioning

confidence: 99%

“…TST is currently the only assay that allows in vivo testing responses to mycobacterial antigens and is still considered a useful tool in TB diagnosis, however high rates of false positive reactions resulting from antigenic similarity between BCG, M . tb and environmental nontuberculous mycobacteria lower its diagnostic usefulness [ 6 , 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CD14-159C/T polymorphism in the development of delayed skin hypersensitivity to tuberculin

et al. 2017

Self Cite

View full text Add to dashboard Cite

The skin tuberculin test (TST), an example of a delayed-type hypersensitivity (DTH) reaction, is based on measuring the extent of skin induration to mycobacterial tuberculin (PPD). Little is known about the genetic basis of TST reactivity, widely used for diagnosing TB infection. The study investigated the relationship of the single base change polymorphic variants in CD14 gene (CD14(-159C/T)) with the development of DTH to PPD in BCG-vaccinated Polish Caucasian individuals. We found persistent lack of TST reactivity in about 40% of healthy subjects despite receiving more than one dose of BCG. The TST size was negatively correlated with the number of BCG inoculations. The distribution of C/T genotype was significantly more frequent among TST-negative compared with TST-positive individuals. The concentration of serum sCD14 was positively associated with mCD14 expression, but not with the TST status or CD14(-159C/T) polymorphism. A significant increase in mCD14 expression and serum sCD14 levels was found in TB group. We hypothesize that CD14(-159C/T) polymorphic variants might be one of genetic components in the response to attenuated M. bovis BCG bacilli.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CD14-159C/T polymorphism in the development of delayed skin hypersensitivity to tuberculin

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…SELL is involved in leukocyte addressing, adhesion, migration, signal transduction and has been shown to discriminate TB from other respiratory diseases 16,17 . Soluble CD14 (sCD14) is known for its role in the recognition pathologies in the lungs including active TB [18][19][20][21][22] . C1q, the rst subcomponent of the classical complement cascade was used to discriminate ATB from latent TB infection [23][24][25] .…”

Section: Introductionmentioning

confidence: 99%

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Ndiaye

Ranaivomanana

Rasoloharimanana

et al. 2022

Preprint

View full text Add to dashboard Cite

Background There is a need for rapid non-sputum-based tests to identify and treat patients infected with Mycobacterium tuberculosis (Mtb). In this study, performance of a human plasma protein signature for both TB triage and treatment monitoring has been evaluated. Methods A panel of seven host proteins CLEC3B, SELL, IGFBP3, IP10, CD14, ECM1 and C1Q were measured in the plasma of a prospective patient cohort undergoing anti-tubercular therapy to distinguish confirmed TB patients from control, to define culture slow and fast converters during an antituberculosis treatment and to monitor the treatment. To validate the protein signatures a Luminex xMAP® assay was used to quantify the proteins in unstimulated plasma isolated from the blood collected from HIV-negative pulmonary TB patients (ATB), at baseline and following 6-months of antituberculosis treatment, latently TB-infected individuals (LTBI) and healthy donors (HD). Protein signatures performances were evaluated using CombiROC algorithm and multivariate models. Findings: We measured the proteins in the plasma of 84 participants including 37 ATB, 24 LTBI and 23 HD. The seven plasma host proteins studied showed different levels between the TB clinical groups and when used separately or in combination, have variable performances for ATB triage and for treatment monitoring. Six of the plasma proteins (CLEC3B, SELL, IGFBP3, IP10, CD14 and C1Q) showed significant differences in normalised median fluorescence intensities when comparing ATB vs HD or LTBI while ECM1 revealed a significant association with early sputum culture conversion after 2 months following treatment (OR 0.004, p = 0.018). For both triage and treatment monitoring, a signature combining 4 host proteins markers (CLEC3B-ECM1-IP10-SELL) was identified, allowing to distinguish ATB from HD or LTBI (respectively, sensitivity = 94%, specificity = 92% and sensitivity = 89%, specificity = 91%) as well as the baseline distinction between slow vs fast sputum culture converters after two months of treatment (AUC = 0.87, sensitivity = 83%, specificity = 84%). Conclusion Our data demonstrate that using a combination of host plasma markers can generate a relevant biosignature for both TB triage and treatment monitoring meeting the WHO Target Product Profile for both purposes.

show abstract

“…Increasing evidence suggests an important role for circulating macrophage-derived biomarkers in blood and other biological fluids that reflect the activation of macrophage population in the clinical assessment of intracellular bacterial infections. Previous studies have shown that increased sCD163 and sCD14 levels are associated with poor outcome in patients with tuberculosis [4][5][6][7][8][9]. For leprosy and leishmaniasis, serum sCD163 levels have also been shown to be indicative of disease severity [10].…”

Section: Introductionmentioning

confidence: 99%

Serum levels of soluble CD163 and soluble CD14 following antibiotic therapy of patients with acute brucellosis

Sun

Jiang

Han

et al. 2019

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Soluble CD163 (sCD163) and soluble CD14 (sCD14) levels, monocyte/macrophage activation markers, are elevated in patient serum during Brucella infection. The aim of this study was to measure serum sCD163 and sCD14 levels during treatment for acute brucellosis to determine whether they can be used to monitor treatment efficacy. Methodology: Blood samples were collected from 30 patients with acute brucellosis (disease duration < 8 weeks) before and after 6 weeks of antibiotic therapy as well as from a comparison group of 28 healthy control individuals. Serum sCD163 and sCD14 levels were measured with specific, sandwich enzyme-linked immunosorbent assays. The clinical data and routine indices including C-reactive protein (CRP), erythrocyte sedimentation rates (ESR), as well as white cell counts (WBC) were also studied. Results: Both serum sCD163 and sCD14 levels were significantly higher in patients with acute brucellosis than in healthy controls (p < 0.0001). A significant decline was observed in patients after cessation of treatment (p < 0.001), which still be significantly higher than that in healthy controls (p < 0.001). In additional, serum sCD163 levels were positively correlated with sCD14 levels; both of which were positively associated with CRP levels. However, neither sCD163 nor sCD14 levels were correlated with ESR or WBC. Conclusions: The decline in sCD163 and sCD14 levels following antibiotic therapy may be used as a marker to assess therapeutic efficacy following treatment of acute brucellosis.

show abstract

Two-Year Follow-up Study of Mycobacterium tuberculosis Antigen-Driven IFN-γ Responses and Macrophage sCD14 Levels After Tuberculosis Contact

Abstract: Clinical data regarding the prediction of active tuberculosis (TB) development in close TB contacts are scarce. To address this problem, we performed a 2-year follow-up study of Mycobacterium tuberculosis (M.tb) antigen-driven IFN-gamma responses and serum levels of

Cited by 4 publications

References 37 publications

CD14-159C/T polymorphism in the development of delayed skin hypersensitivity to tuberculin

CD14-159C/T polymorphism in the development of delayed skin hypersensitivity to tuberculin

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Serum levels of soluble CD163 and soluble CD14 following antibiotic therapy of patients with acute brucellosis

Contact Info

Product

Resources

About